Engineered affinity proteins--generation and applications.
暂无分享,去创建一个
[1] A. Lim,et al. Directed evolution of high-affinity antibody mimics using mRNA display. , 2002, Chemistry & biology.
[2] J. Deisenhofer. Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A from Staphylococcus aureus at 2.9- and 2.8-A resolution. , 1981, Biochemistry.
[3] V. Tolmachev,et al. Pre-clinical evaluation of [111In]-benzyl-DOTA-Z(HER2:342), a potential agent for imaging of HER2 expression in malignant tumors. , 2007, International journal of molecular medicine.
[4] Patrick Amstutz,et al. CD4-Specific Designed Ankyrin Repeat Proteins Are Novel Potent HIV Entry Inhibitors with Unique Characteristics , 2008, PLoS pathogens.
[5] Anthony Williams,et al. DX-88 and HAE: a developmental perspective. , 2003, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.
[6] B. Groner,et al. Peptide aptamers: recent developments for cancer therapy , 2005, Expert opinion on biological therapy.
[7] Eric T. Boder,et al. Yeast surface display for screening combinatorial polypeptide libraries , 1997, Nature Biotechnology.
[8] Arne Skerra,et al. Anticalins as an alternative to antibody technology , 2005, Expert opinion on biological therapy.
[9] G. Magnusson,et al. Use of bacteriophage T7 displayed peptides for determination of monoclonal antibody specificity and biosensor analysis of the binding reaction. , 1999, Analytical biochemistry.
[10] P. Parren,et al. Immunogenicity screening in protein drug development , 2007, Expert opinion on biological therapy.
[11] H. Brismar,et al. Phage display selection of Affibody molecules with specific binding to the extracellular domain of the epidermal growth factor receptor. , 2007, Protein engineering, design & selection : PEDS.
[12] L. Black,et al. Phage T4 SOC and HOC display of biologically active, full-length proteins on the viral capsid. , 1998, Gene.
[13] K. D. Hardman,et al. Single-chain antigen-binding proteins. , 1988, Science.
[14] A. Skerra,et al. Small antibody-like proteins with prescribed ligand specificities derived from the lipocalin fold. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[15] Mathias Uhlén,et al. Microbead display of proteins by cell-free expression of anchored DNA. , 2003, Journal of biotechnology.
[16] J. Scott,et al. Searching for peptide ligands with an epitope library. , 1990, Science.
[17] Vladimir Tolmachev,et al. Radionuclide therapy of HER2-positive microxenografts using a 177Lu-labeled HER2-specific Affibody molecule. , 2007, Cancer research.
[18] B. Moza,et al. Neutralization of staphylococcal enterotoxin B by soluble, high-affinity receptor antagonists , 2007, Nature Medicine.
[19] Jakob Dogan,et al. Structural basis for molecular recognition in an affibody:affibody complex. , 2006, Journal of molecular biology.
[20] Andreas Plückthun,et al. Inhibition of caspase-2 by a designed ankyrin repeat protein: specificity, structure, and inhibition mechanism. , 2007, Structure.
[21] M. Snyder,et al. Analyzing antibody specificity with whole proteome microarrays , 2003, Nature Biotechnology.
[22] Arne Skerra,et al. Alternative binding proteins: Anticalins – harnessing the structural plasticity of the lipocalin ligand pocket to engineer novel binding activities , 2008, The FEBS journal.
[23] Andreas Plückthun,et al. Designing repeat proteins: well-expressed, soluble and stable proteins from combinatorial libraries of consensus ankyrin repeat proteins. , 2003, Journal of molecular biology.
[24] David W. Colby,et al. Potent inhibition of huntingtin aggregation and cytotoxicity by a disulfide bond-free single-domain intracellular antibody. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[25] A. Koide,et al. Probing protein conformational changes in living cells by using designer binding proteins: Application to the estrogen receptor , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[26] S. Gambhir,et al. Covalent disulfide-linked anti-CEA diabody allows site-specific conjugation and radiolabeling for tumor targeting applications. , 2004, Protein engineering, design & selection : PEDS.
[27] M. A. Carrondo,et al. Structure of wild-type Plk-1 kinase domain in complex with a selective DARPin. , 2008, Acta crystallographica. Section D, Biological crystallography.
[28] Andreas Plückthun,et al. Intracellular Kinase Inhibitors Selected from Combinatorial Libraries of Designed Ankyrin Repeat Proteins* , 2005, Journal of Biological Chemistry.
[29] S. Ståhl,et al. Selection and characterization of an HIV‐1 gp120‐binding affibody ligand , 2006, Biotechnology and applied biochemistry.
[30] L. Jendeberg,et al. Kinetic analysis of the interaction between protein a domain variants and human Fc using plasmon resonance detection , 1995, Journal of molecular recognition : JMR.
[31] David E. Golan,et al. Protein therapeutics: a summary and pharmacological classification , 2008, Nature Reviews Drug Discovery.
[32] H. Steven Wiley,et al. Flow-cytometric isolation of human antibodies from a nonimmune Saccharomyces cerevisiae surface display library , 2003, Nature Biotechnology.
[33] G. Adams,et al. In vitro characterization of a bivalent anti-HER-2 affibody with potential for radionuclide-based diagnostics. , 2005, Cancer biotherapy & radiopharmaceuticals.
[34] C. Vanhove,et al. SPECT Imaging with 99mTc-Labeled EGFR-Specific Nanobody for In Vivo Monitoring of EGFR Expression , 2008, Molecular Imaging and Biology.
[35] A. Plückthun,et al. Isolation of Intracellular Proteinase Inhibitors Derived from Designed Ankyrin Repeat Proteins by Genetic Screening* , 2006, Journal of Biological Chemistry.
[36] M. Scholle,et al. Molecular recognition properties of FN3 monobodies that bind the Src SH3 domain. , 2004, Chemistry & biology.
[37] M. Uhlén,et al. Staphylococcal protein A consists of five IgG-binding domains. , 1986, European journal of biochemistry.
[38] Jodi R Parrish,et al. Yeast two-hybrid contributions to interactome mapping. , 2006, Current opinion in biotechnology.
[39] Y Husimi,et al. In vitro virus: Bonding of mRNA bearing puromycin at the 3′‐terminal end to the C‐terminal end of its encoded protein on the ribosome in vitro , 1997, FEBS letters.
[40] A. Bruskin,et al. Imaging of HER2-expressing tumours using a synthetic Affibody molecule containing the 99mTc-chelating mercaptoacetyl-glycyl-glycyl-glycyl (MAG3) sequence , 2007, European Journal of Nuclear Medicine and Molecular Imaging.
[41] S. Hober,et al. Development of affinity columns for the removal of high‐abundance proteins in cerebrospinal fluid , 2009 .
[42] G. P. Smith,et al. Antibody-selectable filamentous fd phage vectors: affinity purification of target genes. , 1988, Gene.
[43] M. Uhlén,et al. Recombinant human factor VIII-specific affinity ligands selected from phage-displayed combinatorial libraries of protein A. , 2001, European journal of biochemistry.
[44] M. Uhlén,et al. A synthetic IgG-binding domain based on staphylococcal protein A. , 1987, Protein engineering.
[45] N. Damle,et al. Biopharmaceutical drug discovery using novel protein scaffolds. , 2006, Current opinion in biotechnology.
[46] David E. Gloriam,et al. ProteomeBinders: planning a European resource of affinity reagents for analysis of the human proteome , 2007, Nature Methods.
[47] A. Bradbury,et al. Antibodies from phage antibody libraries. , 2004, Journal of immunological methods.
[48] S. Brenner,et al. Surface Display of Proteins on Bacteriophage λ Heads , 1996 .
[49] M. Uhlén,et al. Anti‐idiotypic protein domains selected from protein A‐based affibody libraries , 2002, Proteins.
[50] M. Dennis,et al. Kunitz domain inhibitors of tissue factor-factor VIIa. I. Potent inhibitors selected from libraries by phage display. , 1994, The Journal of biological chemistry.
[51] A. Karlström,et al. Dual labeling of a binding protein allows for specific fluorescence detection of native protein. , 2001, Analytical biochemistry.
[52] Dan S. Tawfik,et al. Microbead display by in vitro compartmentalisation: selection for binding using flow cytometry , 2002, FEBS letters.
[53] P. Hudson,et al. Engineered antibody fragments and the rise of single domains , 2005, Nature Biotechnology.
[54] P. Nordlund,et al. Structural basis for recognition by an in vitro evolved affibody , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[55] D. Coomber,et al. CIS display: In vitro selection of peptides from libraries of protein-DNA complexes. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[56] H R Hoogenboom,et al. Natural and designer binding sites made by phage display technology. , 2000, Immunology today.
[57] P. Carter. Potent antibody therapeutics by design , 2006, Nature Reviews Immunology.
[58] S. Ståhl,et al. Generation of Affibody® ligands binding interleukin‐2 receptor α/CD25 , 2008, Biotechnology and applied biochemistry.
[59] E. Lundberg,et al. Selection and characterization of Affibody® ligands to the transcription factor c‐Jun , 2009, Biotechnology and applied biochemistry.
[60] Z. Xu,et al. Inhibition of the CD28-CD80 co-stimulation signal by a CD28-binding affibody ligand developed by combinatorial protein engineering. , 2003, Protein engineering.
[61] H. Wernérus,et al. Evaluation of Staphylococcal Cell Surface Display and Flow Cytometry for Postselectional Characterization of Affinity Proteins in Combinatorial Protein Engineering Applications , 2007, Applied and Environmental Microbiology.
[62] C. Hovens,et al. Mutagenesis and selection of PDZ domains that bind new protein targets , 1999, Nature Biotechnology.
[63] A. Plückthun,et al. Directed in Vitro Evolution and Crystallographic Analysis of a Peptide-binding Single Chain Antibody Fragment (scFv) with Low Picomolar Affinity* , 2004, Journal of Biological Chemistry.
[64] A. Karlström,et al. Fluorescence resonance energy transfer-based detection of analytes using antiidiotypic affinity protein pairs. , 2004, Analytical biochemistry.
[65] R. Bruccoleri,et al. Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[66] M. Uhlén,et al. A novel affinity gene fusion system allowing protein A-based recovery of non-immunoglobulin gene products. , 2002, Journal of biotechnology.
[67] L. Abrahmsén,et al. Affibody molecules: potential for in vivo imaging of molecular targets for cancer therapy , 2007, Expert opinion on biological therapy.
[68] H. Berglund,et al. An affibody in complex with a target protein: Structure and coupled folding , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[69] S. Hober,et al. Affibody-mediated transferrin depletion for proteomics applications. , 2007, Biotechnology journal.
[70] V. Tolmachev,et al. Affibody molecules: new protein domains for molecular imaging and targeted tumor therapy. , 2007, Current opinion in drug discovery & development.
[71] C. Barbas,et al. Phage display of combinatorial antibody libraries. , 1997, Current opinion in biotechnology.
[72] John Löfblom,et al. A novel affinity protein selection system based on staphylococcal cell surface display and flow cytometry. , 2008, Protein engineering, design & selection : PEDS.
[73] J. Wells,et al. Hormone phage: An enrichment method for variant proteins with altered binding properties , 1990, Proteins.
[74] Matthias Paschke,et al. Phage display systems and their applications , 2006, Applied Microbiology and Biotechnology.
[75] E. Johansson,et al. Directed evolution to low nanomolar affinity of a tumor-targeting epidermal growth factor receptor-binding affibody molecule. , 2008, Journal of molecular biology.
[76] Motomu Shimaoka,et al. Directed evolution to probe protein allostery and integrin I domains of 200,000-fold higher affinity. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[77] G. Winter,et al. Phage antibodies: filamentous phage displaying antibody variable domains , 1990, Nature.
[78] V. Streltsov,et al. Structure of a shark IgNAR antibody variable domain and modeling of an early‐developmental isotype , 2005, Protein science : a publication of the Protein Society.
[79] H. Binz,et al. DARPins: a new generation of protein therapeutics. , 2008, Drug discovery today.
[80] G. Adams,et al. Selection and characterization of HER2/neu-binding affibody ligands. , 2004, Protein engineering, design & selection : PEDS.
[81] N. Habib,et al. Adenovirus 5 vector genetically re-targeted by an Affibody molecule with specificity for tumor antigen HER2/neu , 2007, Cancer Gene Therapy.
[82] H. de Haard,et al. Properties, production, and applications of camelid single-domain antibody fragments , 2007, Applied Microbiology and Biotechnology.
[83] S. Koide,et al. Phage display for engineering and analyzing protein interaction interfaces. , 2007, Current opinion in structural biology.
[84] P. Daugherty. Protein engineering with bacterial display. , 2007, Current opinion in structural biology.
[85] R. Pehrson,et al. Synthetic affibody molecules: a novel class of affinity ligands for molecular imaging of HER2-expressing malignant tumors. , 2007, Cancer research.
[86] George Georgiou,et al. Anchored periplasmic expression, a versatile technology for the isolation of high-affinity antibodies from Escherichia coli-expressed libraries. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[87] A. Plückthun,et al. Rapid selection of specific MAP kinase-binders from designed ankyrin repeat protein libraries. , 2006, Protein engineering, design & selection : PEDS.
[88] Jinha M. Park,et al. Characterization of engineered anti-p185HER-2 (scFv-CH3)2 antibody fragments (minibodies) for tumor targeting. , 2004, Protein engineering, design & selection : PEDS.
[89] Andreas Plückthun,et al. Allosteric inhibition of aminoglycoside phosphotransferase by a designed ankyrin repeat protein. , 2005, Structure.
[90] M. Uhlén,et al. All individual domains of staphylococcal protein A show Fab binding. , 2006, FEMS immunology and medical microbiology.
[91] A. Koide,et al. The fibronectin type III domain as a scaffold for novel binding proteins. , 1998, Journal of molecular biology.
[92] L. James,et al. Crystal structure of HEL4, a soluble, refoldable human V(H) single domain with a germ-line scaffold. , 2004, Journal of molecular biology.
[93] H. Brumer,et al. Chemical Synthesis of Triple‐Labelled Three‐Helix Bundle Binding Proteins for Specific Fluorescent Detection of Unlabelled Protein , 2005, Chembiochem : a European journal of chemical biology.
[94] T. Härd,et al. Stabilization of a β-hairpin in monomeric Alzheimer's amyloid-β peptide inhibits amyloid formation , 2008, Proceedings of the National Academy of Sciences.
[95] A. Plückthun,et al. In vitro selection and evolution of functional proteins by using ribosome display. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[96] M. Uhlén,et al. Construction and characterization of affibody-Fc chimeras produced in Escherichia coli. , 2002, Journal of immunological methods.
[97] A. Skerra,et al. A novel type of receptor protein, based on the lipocalin scaffold, with specificity for digoxigenin. , 2000, Journal of molecular biology.
[98] A. Plückthun,et al. High-affinity binders selected from designed ankyrin repeat protein libraries , 2004, Nature Biotechnology.
[99] A. Karlström,et al. Affibody protein capture microarrays: synthesis and evaluation of random and directed immobilization of affibody molecules. , 2005, Analytical biochemistry.
[100] P. Nygren,et al. Binding proteins from alternative scaffolds. , 2004, Journal of immunological methods.
[101] George Georgiou,et al. Isolation of engineered, full-length antibodies from libraries expressed in Escherichia coli , 2007, Nature Biotechnology.
[102] James Inglese,et al. Directed evolution of PDZ variants to generate high-affinity detection reagents. , 2005, Protein engineering, design & selection : PEDS.
[103] P. Nygren,et al. Alternative binding proteins: Affibody binding proteins developed from a small three‐helix bundle scaffold , 2008, The FEBS journal.
[104] E. Lundberg,et al. Site-specifically conjugated anti-HER2 Affibody molecules as one-step reagents for target expression analyses on cells and xenograft samples. , 2007, Journal of immunological methods.
[105] S. Sidhu. Phage display in pharmaceutical biotechnology. , 2000, Current opinion in biotechnology.
[106] R. Barrett,et al. Peptides on phage: a vast library of peptides for identifying ligands. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[107] S. Lindström,et al. Selection and characterization of Affibody ligands binding to Alzheimer amyloid β peptides , 2007 .
[108] W. Dower,et al. An in vitro polysome display system for identifying ligands from very large peptide libraries. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[109] W. Stemmer,et al. Multivalent avimer proteins evolved by exon shuffling of a family of human receptor domains , 2005, Nature biotechnology.
[110] C. Barbas,et al. Linkage of recognition and replication functions by assembling combinatorial antibody Fab libraries along phage surfaces. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[111] C. Borrebaeck,et al. Antibodies in diagnostics - from immunoassays to protein chips. , 2000, Immunology today.
[112] C. Barbas,et al. Assembly of combinatorial antibody libraries on phage surfaces: the gene III site. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[113] Lucy J. Holt,et al. Domain antibodies: proteins for therapy. , 2003, Trends in biotechnology.
[114] M. Uhlén,et al. Human immunoglobulin A (IgA)-specific ligands from combinatorial engineering of protein A. , 2002, European journal of biochemistry.
[115] W. Arap,et al. Display technologies: Application for the discovery of drug and gene delivery agents , 2006, Advanced Drug Delivery Reviews.
[116] M. Uhlén,et al. Binding proteins selected from combinatorial libraries of an α-helical bacterial receptor domain , 1997, Nature Biotechnology.
[117] M. Uhlén,et al. Ligands selected from combinatorial libraries of protein A for use in affinity capture of apolipoprotein A-1M and taq DNA polymerase. , 2000, Journal of biotechnology.
[118] J. Carlsson,et al. Tumor imaging using a picomolar affinity HER2 binding affibody molecule. , 2006, Cancer research.
[119] M. Michel-beyerle,et al. Ultrafast electron transfer in the complex between fluorescein and a cognate engineered lipocalin protein, a so-called anticalin. , 2002, Biochemistry.
[120] M. Uhlén,et al. A combinatorial library of an α-helical bacterial receptor domain , 1995 .
[121] Xianghua Yan,et al. Ribosome-display technology: applications for directed evolution of functional proteins. , 2006, Drug discovery today.
[122] K D Wittrup,et al. Yeast surface display for directed evolution of protein expression, affinity, and stability. , 2000, Methods in enzymology.
[123] E. Lundberg,et al. Affinity-based entrapment of the HER2 receptor in the endoplasmic reticulum using an affibody molecule. , 2008, Journal of immunological methods.
[124] J. Devlin,et al. Random peptide libraries: a source of specific protein binding molecules. , 1990, Science.
[125] Vladimir Tolmachev,et al. 111In-benzyl-DTPA-ZHER2:342, an affibody-based conjugate for in vivo imaging of HER2 expression in malignant tumors. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[126] G. Georgiou,et al. Production and fluorescence-activated cell sorting of Escherichia coli expressing a functional antibody fragment on the external surface. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[127] S. Ståhl,et al. Re-targeted adenovirus vectors with dual specificity; binding specificities conferred by two different Affibody molecules in the fiber , 2009, Gene Therapy.
[128] Andreas Plückthun,et al. In-vitro protein evolution by ribosome display and mRNA display. , 2004, Journal of immunological methods.
[129] Y. Husimi,et al. An in vitro DNA virus for in vitro protein evolution , 2001, FEBS letters.
[130] K Dane Wittrup,et al. Yeast surface display for protein engineering and characterization , 2007, Current Opinion in Structural Biology.
[131] Andreas Plückthun,et al. Direct selection of antibodies from complex libraries with the protein fragment complementation assay. , 2006, Journal of molecular biology.
[132] M. Uhlén,et al. Affinity maturation of a Taq DNA polymerase specific affibody by helix shuffling. , 1999, Protein engineering.
[133] R. Hoess,et al. Protein design and phage display. , 2001, Chemical reviews.
[134] Carlos F. Barbas,et al. Phage display: a Laboratory manual , 2014 .
[135] A. P. Chapman,et al. PEGylated antibodies and antibody fragments for improved therapy: a review. , 2002, Advanced drug delivery reviews.
[136] A. Mire-Sluis,et al. Immune responses to therapeutic proteins in humans--clinical significance, assessment and prediction. , 2002, Current pharmaceutical biotechnology.
[137] Caroline Kampf,et al. Affibody-beta-galactosidase immunoconjugates produced as soluble fusion proteins in the Escherichia coli cytosol. , 2003, Journal of immunological methods.
[138] T Prospero,et al. "Diabodies": small bivalent and bispecific antibody fragments. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[139] Dario Neri,et al. Selection of single domain binding proteins by covalent DNA display. , 2007, Protein engineering, design & selection : PEDS.
[140] G. Georgiou,et al. Antibody affinity maturation using bacterial surface display. , 1998, Protein engineering.
[141] M. Geiser,et al. Evaluation of antibodies fused to minor coat protein III and major coat protein VIII of bacteriophage M13. , 1995, Gene.
[142] M. Uhlén,et al. Affibody molecules in protein capture microarrays: evaluation of multidomain ligands and different detection formats. , 2007, Journal of proteome research.
[143] C. Briand,et al. Drug Export Pathway of Multidrug Exporter AcrB Revealed by DARPin Inhibitors , 2006, PLoS biology.
[144] M. Vogel,et al. Designed Ankyrin Repeat Proteins as Anti‐Idiotypic‐Binding Molecules , 2007, Annals of the New York Academy of Sciences.
[145] L E Williams,et al. Minibody: A novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid, high-level targeting of xenografts. , 1996, Cancer research.
[146] Gary Walsh,et al. Biopharmaceuticals: recent approvals and likely directions. , 2005, Trends in biotechnology.
[147] R. Rudolph,et al. Artificial, non-antibody binding proteins for pharmaceutical and industrial applications. , 2005, Trends in biotechnology.
[148] Fine affinity discrimination by normalized fluorescence activated cell sorting in staphylococcal surface display. , 2005, FEMS microbiology letters.
[149] R. Cortese,et al. Efficient display of an HCV cDNA expression library as C-terminal fusion to the capsid protein D of bacteriophage lambda. , 1998, Journal of molecular biology.
[150] A. Skerra. Alternative non-antibody scaffolds for molecular recognition. , 2007, Current opinion in biotechnology.
[151] Lin Sun,et al. Antagonists to human and mouse vascular endothelial growth factor receptor 2 generated by directed protein evolution in vitro. , 2006, Chemistry & biology.
[152] K Dane Wittrup,et al. Isolating and engineering human antibodies using yeast surface display , 2006, Nature Protocols.
[153] Andreas Plückthun,et al. Ribosome display: selecting and evolving proteins in vitro that specifically bind to a target , 2007, Nature Methods.
[154] B. Power,et al. A new generation of protein display scaffolds for molecular recognition , 2006, Protein science : a publication of the Protein Society.
[155] G. P. Smith,et al. Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. , 1985, Science.
[156] P. Diot,et al. EPI-hNE4, a Proteolysis-Resistant Inhibitor of Human Neutrophil Elastase and Potential Anti-Inflammatory Drug for Treating Cystic Fibrosis , 2006, Journal of Pharmacology and Experimental Therapeutics.
[157] A. Plückthun,et al. Engineering novel binding proteins from nonimmunoglobulin domains , 2005, Nature Biotechnology.
[158] M. Uhlén,et al. An in vitro selected binding protein (affibody) shows conformation-dependent recognition of the respiratory syncytial virus (RSV) G protein. , 1999, Immunotechnology : an international journal of immunological engineering.
[159] Y. Cho,et al. Mining a yeast library for brain endothelial cell-binding antibodies , 2007, Nature Methods.
[160] R. Roberts. Totally in vitro protein selection using mRNA-protein fusions and ribosome display. , 1999, Current opinion in chemical biology.
[161] J W Szostak,et al. RNA-peptide fusions for the in vitro selection of peptides and proteins. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[162] Andreas Plückthun,et al. A designed ankyrin repeat protein evolved to picomolar affinity to Her2. , 2007, Journal of molecular biology.
[163] M. Uhlén,et al. Epitope mapping of antibodies using bacterial surface display , 2008, Nature Methods.
[164] Jenny Rönnmark,et al. Inclusion of a non-immunoglobulin binding protein in two-site ELISA for quantification of human serum proteins without interference by heterophilic serum antibodies. , 2003, Journal of immunological methods.